[Plasma non-ceruloplasmin copper in hepatocerebral dystrophy (criterion for the diagnosis and evaluation of cuprogogue therapy)].
Results of determining the plasma levels of non-coeruloplasmin copper in 29 patients with hepatocerebral dystrophy (before and during cuprogogue therapy) and in 15 practically healthy individuals are presented. A statistically significant rise of this level (as compared with that in the control group) was revealed in the patients with Wilson-Konovaloff's disease. The clinical improvement of the patients with hepatocerebral dystrophy was accompanied by normalization of the plasma level of non-coeruloplasmin copper. This gives one grounds to conclude that this parameter can be used as a criterion for evaluating the efficacy of the treatment given.
D003300:Copper / Q000097:blood*; D006527:Hepatolenticular Degeneration / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D010396:Penicillamine / Q000627:therapeutic use*
D003300:Copper; D010396:Penicillamine
Netseruloplazminovaia med' plazmy pri gepatotserebral'noĭ distrofii (kriteriĭ diagnostiki i otsenki éffektivnosti medegonnoĭ terapii).